AzTrials
AzTrials

Childhood Cancer SurvivorsNCT07120646

Pain and Sleep Disturbances in Children Living Beyond Cancer: A Case-Control Study

An observational study of Childhood Cancer Survivors, run by Vrije Universiteit Brussel at 2 sites in Belgium.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Children living beyond cancer (CBC) represent a unique and growing population of young people in need of long-term clinical support. Studies suggest that 11-44% of CBC experience chronic pain, negatively impacting a wide range of child biopsychosocial outcomes and creating high financial burden for their families and… Read more about this study

Who is it for?
Ages 6 to 12 yearsHealthy volunteers can take part
Conditions the study is for
Childhood Cancer Survivors
What is being tested?
Questionnaire, actigraphy measurement and sleep diary
How many people
76 participants
Where
2 sitesBelgium
Study dates
1 Oct 2025to Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 12 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Study population: Children living beyond cancer (6-12 years old) and age- and sex-matched healthy controls, together with one of their parents.

Who may be able to join

  • CBC: 1) current age 6-12yo; 2) history of any cancer diagnosis; 3) ≤ 5y post- treatment completion; 4) ≥ 3 months since last cancer treatment (since pain and insomnia during treatment can be directly related to therapy and recover spontaneously); 5) fluent Dutch speaker and reader (age-dependent)
  • Healthy controls (age- and sex-matched): 1) current age 6-12yo; 2) no history of cancer ; 3) fluent Dutch/French/English speaker and reader (age-dependent)
  • Parents: 1) fluent Dutch/French/English speaker and reader

Who cannot join

  • CBC: 1) receiving palliative therapy; 2) psychiatric disorder; 3) severe intellectual disability
  • Healthy controls: 1) history of cancer; 2) psychiatric disorder; 3) severe intellectual disability

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Emma Rheel, PhD contact

+32496908353

emma.rheel@vub.be

Nijs Jo, PhD contact

+32496908353

jo.nijs@vub.be

Belgium2 sites, 2 recruiting
  • Vrije Universiteit Brussel

    Brussels, Brussels Capital, 1090

    Emma Rheel, PhD, +32496908353, emma.rheel@vub.be

    Recruiting
  • Vrije Universiteit Brussel

    Jette, Brussels Capital, 1090

    Emma Rheel, PhD, +32496908353, emma.rheel@vub.be

    Emma Rheel, PhD

    Not yet recruiting

Other trials in Belgium

About this study

Official title: The Co-Morbidity of Pain and Sleep Disturbances in Children Living Beyond Cancer: A Case-Control Study

Children living beyond cancer (CBC) represent a unique and growing population of young people in need of long-term clinical support. Studies suggest that 11-44% of CBC experience chronic pain, negatively impacting a wide range of child biopsychosocial outcomes and creating high financial burden for their families and society. Often comorbid with pain, one of the most chronic and disturbing side effects reported by CBC are sleep disturbances, and in particular, difficulties initiating and maintaining sleep. Indeed, >50% of CBC report some form of sleep disturbance even 9 to 15 years after the cancer diagnosis. Much attention has been paid to sleep and pain as independent constructs within pediatric oncology, yet Belgian data is lacking. Additionally, little is known about how these domains interact with one another and subsequent indications for prevention and intervention. Although evidence shows an interrelationship between pain and sleep in adult and pediatric populations, this interrelationship is understudied in childhood cancer patients and CBC. (Chronic) pain may serve as a modifiable target for interventions to improve sleep quality and vice versa, and understanding this relationship is crucial for providing comprehensive care to CBC. Therefore, this cross-sectional case-control study aims to explore the differences in pain and sleep disturbances in CBC compared to healthy age- and sex-matched healthy controls, as well as the interrelationship between both outcomes.

Read the detailed description

Pain and sleep disturbances are common and impactful following childhood cancer treatment

Worldwide, about 400 000 children aged 0-19 years are diagnosed with cancer each year. Largely due to more intensive treatment regimens and the implementation of immunotherapy for high-risk patients, 5-year survival rates for children with cancer in high income countries have increased to >80%. This is great news, however as a result, children living beyond cancer (CBC) represent a unique and growing population of young people in need of long-term clinical support.

Across the cancer continuum, pain is a prevalent, recurrent, and impactful symptom. Although we know that pain in childhood cancer is underreported and undertreated, the prevalence of pain in children during active cancer treatment varies from 28-62% across studies, with >50% of children reporting moderate to severe pain intensity. For many children, pain resolves following completion of the cancer treatment, yet for some, pain persists well beyond treatment7 and into adulthood. Indeed, studies suggest that 11-44% of CBC experience chronic pain (i.e., pain in ≥ 1 anatomic region persisting or recurring for >3 months), with 20% reporting moderate to extreme pain interference. Chronic pain can deleteriously impact the lives of CBC and their family. Specifically, if not addressed early on, chronic pain can negatively impact children's school functioning, sleep quality, social and family functioning, mental health, physical activity, and overall health-related quality of life. Moreover, it increases the risk of chronic pain across the lifespan. Further, also the families of children with chronic pain can experience significant physical and psychosocial sequelae due to the child's pain, e.g., high levels of anxiety and depressive symptoms, and a high financial burden due to direct and indirect medical costs.

Often comorbid with pain, one of the most chronic and disturbing side effects reported by childhood cancer patients and CBC are sleep disturbances, and in particular, difficulties initiating and maintaining sleep, suggesting that this is a major quality of life concern. Indeed, >50% of CBC report some form of sleep disturbance even 9 to 15 years after the cancer diagnosis. Good-quality sleep in childhood is crucial for a healthy emotional, cognitive, physical, and behavioral development. Healthy sleep involves receiving a developmentally appropriate number of hours of sleep (declining from infancy to adolescence), few or preferably no wakings during the night, and a subjective perception of feeling rested. CBC may be at increased risk for sleep disturbances, being critically ill during a life phase that is important in the development of good sleep habits. Disrupted sleep can also affect inflammatory pathways and immune functioning, incl. natural killer cell activity, and can contribute to or exacerbate other morbidities common to survivorship (e.g., anxiety, depression). Sleep disruption is unlikely to remit without intervention and longitudinal research shows that sleep disruption often persists from childhood into adolescence.

Study Rationale and Purpose

Some attention has been paid to sleep and pain as independent constructs within pediatric oncology, although Belgian data is lacking and little is known about how these domains interact with one another and subsequent indications for prevention and intervention. Early studies propose a bi-directional relationship between pain and sleep, such that sleep deficiency and pain reciprocally maintain symptoms over time. Yet, the interrelationship between pain and sleep is understudied in childhood cancer patients and CBC. (Chronic) pain may serve as a modifiable target for interventions to improve sleep quality and vice versa, and understanding this relationship is crucial for providing comprehensive care to CBC.

This cross-sectional case-control study aims to explore the differences in pain and sleep disturbances in CBC (6-12 years old) compared to healthy age- and sex-matched healthy controls, as well as the interrelationship between both outcomes.

Being tested
Questionnaire, actigraphy measurement and sleep diary
Keywords
children living beyond cancer, pain, sleep disturbances, case-control
Medical subject headings
Pain, Parasomnias

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Questionnaire, actigraphy measurement and sleep diaryOther

    Baseline questionnaires (measuring socio-demographic and health-related information, as well as most outcome measures), followed by 2 weeks of actigraphy measurement and daily sleep diary.

Study groups in NCT07120646
Study groupRoleWhat they receive
children living beyond cancer (CBC)Not described
Receives: Other: Questionnaire, actigraphy measurement and sleep diary
healthy controlsage- and sex-matched healthy controls
Receives: Other: Questionnaire, actigraphy measurement and sleep diary

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Activity limitations due to pain

    Measured with the Child Activity Limitations Interview (CALI) - 9 (parent-report version for the 6-7 year-olds; self-report version for the 8-12 year-olds)

    Measured: Baseline about the past 14 days + 14 days following baseline in daily sleep diary

  2. Sleep disturbances

    Assessed with the PROMIS Parent Proxy Item Bank v1.0 - Sleep Disturbance - Short Form 8a parent-report for the 6-7 year olds and PROMIS Pediatric Item Bank v1.0 - Sleep Disturbance - Short Form 8a for the 8-12 year-olds. Additionally, this outcome measure is assessed with the Children's Sleep Habits Questionnaire (CSHQ) (parent-report for all ages).

    Measured: Baseline

Secondary outcomes (15)
  1. Pain severity

    Assessed with the Pain Frequency Severity Duration scale (PFSD) (parent-report for the 6-7 year-olds; self-report for the 8-12 year-olds)

    Measured: Baseline

  2. Pain coping

    Assessed with the Pain Coping Questionnaire short form (parent-report for the 6-7 year-olds; self-report for the 8-12 year-olds)

    Measured: Baseline

  3. Pain reporting and assessment during follow-up care

    Assessed using a selfmade set of items about pain reporting and assessment during medical follow-up consultations

    Measured: Baseline

  4. Health-related quality of life

    Assessed with the PedsQL Generic Score Scales 4.0 (5-7yo parent-report) for the 6-7 year-olds and the PedsQL Generic Score Scales 4.0 (8-12yo self-report) for the 8-12 year-olds.

    Measured: Baseline

  5. Fatigue

    Assessed with the PedsQL Multidimensional Fatigue Scale 3.0 (5-7yo parent-report) for the 6-7 year-olds and the PedsQL Multidimensional Fatigue Scale 3.0 (8-12yo self-report) for the 8-12 year-olds.

    Measured: Baseline

  6. Anxiety

    Assessed with the PROMIS Parent Proxy 3.0 - Anxiety - Short Form 8a for 6-7 year-olds and the PROMIS Pediatric 3.0 - Anxiety - Short Form 8a for the 8-12 year-olds.

    Measured: Baseline

  7. Depressive symptoms

    Assessed with the PROMIS Parent Proxy 3.0 - Depressive Symptoms - Short Form 6a for the 6-7 year-olds and the PROMIS Pediatric 3.0 - Depressive Symptoms - Short Form 6a for the 8-12 year-olds.

    Measured: Baseline

  8. Total sleep time

    The total amount of time scored as sleep in minutes from sleep onset to sleep offset. Assessed with Actigraphy (Fitbit Sense 2)

    Measured: 14 days following baseline

  9. Wake minutes after sleep onset

    The number of minutes scored as wake after nighttime sleep onset. Assessed with Actigraphy (Fitbit Sense 2)

    Measured: 14 days following baseline

  10. Sleep efficiency

    The ratio of total sleep time and total time spent in bed at night as a percentage, with values closer to 100 indicating more efficient sleep. Assessed with Actigraphy (Fitbit Sense 2)

    Measured: 14 days following baseline

  11. Sleep regularity index

    Similarity of the child's sleep-wake pattern from one day to the next based on binary sleep-wake time series. Assessed with Actigraphy (Fitbit Sense 2)

    Measured: 14 days following baseline

  12. Pain symptoms during the day

    This data is collected via a daily sleep diary and includes: presence of pain (yes/no), and if yes; mean and worst pain during the day (0 = no pain; 10 = worst pain possible)

    Measured: 14 days following baseline

  13. Medication intake during the day

    This data is collected via a daily sleep diary and includes whether the child took medication during the day (yes/no), and if yes; which medication.

    Measured: 14 days following baseline

  14. Pain catastrophizing

    Child pain catastrophizing and parental pain catastrophizing, measured with the Pain Catastrophizing Scale for Children (PCS-C) (for 8-12yo) and Pain Catastrophizing Scale for Parents (PCS-P) (for all parents), respectively. The PCS consists of 13 statements that assess thoughts and feelings about pain experiences. Each statement is scored on a 5-point Likert scale, with higher scores indicating a greater degree of catastrophizing. The total score ranges from 0 to 52, with higher scores indicating higher levels of catastrophizing.

    Measured: Baseline

  15. Fear of Cancer Recurrence

    Fear of Cancer Recurrence, measured with the Fear of Cancer Recurrence Inventory Short Form - Child Version (FCRI-C) (for 8-12yo) and Fear of Cancer Recurrence Inventory Short Form - Parent Version (FCRI-P) (for all parents), respectively. The scale consists of 9 items assessing the severity of participants' FRC. The maximum score is 36, with score of 13 and above indicating the presence of "significant" FCR; score of 16 and above indicating the presence of "clinically significant" FCR; and score of 22 and above indicating the presence of "pathological" severe FCR (needing specialized intervention for FCR).

    The FCRI-C was translated for this study using forward-backward translation, pilot-tested with the first 11 participants in the study, re-evaluated following pilot-testing, and afterwards validated with the remaining participants during the course of this study.

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Aug 2025
  2. Study start1 Oct 2025
  3. Primary completionDec 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
76 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07120646
Sponsor's protocol ID
PEEPTrial_CaseControl
Status last verified
Aug 2026
First submitted
26 Jun 2025
Last updated
15 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be documented both at the project level and at the data level: Data level: * In research papers; * Information about variables using labels and variables derivations Project level * Documentation about the authors, background, aims, objectives, and the hypotheses that shape the research * Data collection protocol \& procedures * Project meeting reports Descriptive metadata of data items will be registered in Pure Database with restricted acces (closed access, only on reasonable request). In addition, the raw dataset will include labels in the .xlsx file including variable information providing documentation at the data level. Datasets will be accompanied by a separate word.doc file providing study-level documentation including the field methods used for data collection.

Questions about this trial

What is this clinical trial studying?

An observational study of Childhood Cancer Survivors, run by Vrije Universiteit Brussel at 2 sites in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 15 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Emma Rheel, PhD (+32496908353, emma.rheel@vub.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Activity limitations due to pain (time frame: Baseline about the past 14 days + 14 days following baseline in daily sleep diary). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in